Cas:588730-01-2 N-(6-bromo-[1,3]thiazolo[5,4-b]pyridin-2-yl)benzamide manufacturer & supplier

Chemical Name:N-(6-bromo-[1,3]thiazolo[5,4-b]pyridin-2-yl)benzamide

CAS.NO:588730-01-2

Synonyms:N-(6-bromo-thiazolo[5,4-b]pyridine-2-yl)-benzamide;N-(6-Bromothiazolo[5,4-b]pyridin-2-yl)benzamide

Molecular Formula:C₁₃H₈BrN₃OS

Molecular Weight:334.19100

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.718g/cm3

Index of Refraction:1.771

PSA:83.12000

Exact Mass:332.95700

LogP:3.77910

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N-(6-bromo-thiazolo[5,4-b]pyridine-2-yl)-benzamide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-(6-Bromothiazolo[5,4-b]pyridin-2-yl)benzamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-(6-bromo-thiazolo[5,4-b]pyridine-2-yl)-benzamide Use and application,N-(6-bromo-thiazolo[5,4-b]pyridine-2-yl)-benzamide technical grade,usp/ep/jp grade.

Related News: As the global generic drug market booms and the international API industry accelerates its transfer to developing countries, China and India rely on cost advantages to rapidly grow into major API producers and exporters. N-(6-bromo-[1,3]thiazolo[5,4-b]pyridin-2-yl)benzamide manufacturer The Company��s immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). N-(6-bromo-[1,3]thiazolo[5,4-b]pyridin-2-yl)benzamide supplier But it has been barred from that body as Beijing has increased pressure on Taiwan under President Tsai Ing-wen, who is skeptical about closer ties with China. N-(6-bromo-[1,3]thiazolo[5,4-b]pyridin-2-yl)benzamide vendor As the global generic drug market booms and the international API industry accelerates its transfer to developing countries, China and India rely on cost advantages to rapidly grow into major API producers and exporters. N-(6-bromo-[1,3]thiazolo[5,4-b]pyridin-2-yl)benzamide factory It is understood that at present, the industry competition for global characteristic APIs has shown a development trend of vertical integration, and the number of mergers and acquisitions between pharmaceutical manufacturers and API manufacturers is increasing.